William H Herman1, Barbara H Braffett2, Shihchen Kuo3, Joyce M Lee4, Michael Brandle5, Alan M Jacobson6, Lisa A Prosser7, John M Lachin2. 1. Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI, United States of America. Electronic address: wherman@umich.edu. 2. The Biostatistics Center, George Washington University, Washington, DC, United States of America. 3. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States of America. 4. Pediatric Endocrinology, Child Health Evaluation and Research Unit, University of Michigan, Ann Arbor, MI, United States of America. 5. Division of Endocrinology and Diabetes, Kantonsspital St. Gallen, Sankt Gallen, SG, Switzerland. 6. Winthrop-University Hospital, Mineola, NY, United States of America. 7. Department of Pediatrics, University of Michigan, Ann Arbor, MI, United States of America.
Abstract
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy for type 1 diabetes delayed the development of microvascular and neuropathic complications compared to conventional therapy. At the end of DCCT, all participants were trained in intensive therapy, care was transferred to community providers, and the difference in HbA1c between treatment groups narrowed and disappeared. Our objective was to describe the outcomes and the quality-of-life and costs associated with those outcomes in participants who maintained excellent vs. poor glycemic control over 30 years. RESEARCH DESIGN AND METHODS: We assessed the incidence of retinopathy, nephropathy, neuropathy, cardiovascular disease, acute metabolic complications, death, quality-of-life, and costs in the tertile of DCCT intensive therapy participants who achieved a mean updated HbA1c of <7.2% (55 mmol/mol) and the tertile of DCCT conventional therapy participants (n = 240) who achieved a mean updated HbA1c of >8.8% (73 mmol/mol) over 30 years. RESULTS: Thirty years of excellent vs. poor glycemic control substantially reduced the incidence of retinopathy requiring laser therapy (5% vs. 45%), end-stage renal disease (0% vs. 5%), clinical neuropathy (15% vs. 50%), myocardial infarction (3% vs. 5%), stroke (0.4% vs. 2%), and death (6% vs. 20%). It also resulted in a gain of ~1.62 quality-adjusted life-years and averted ~$90,900 in costs of complications per participant. CONCLUSIONS: Thirty years of excellent vs. poor glycemic control for T1DM can substantially reduce the incidence of complications, comorbidities, and death, improve quality-of-life, and reduce costs. These estimates represent the benefits that may be achieved with excellent glycemic control.
OBJECTIVE: The Diabetes Control and Complications Trial (DCCT) demonstrated that intensive therapy for type 1 diabetes delayed the development of microvascular and neuropathic complications compared to conventional therapy. At the end of DCCT, all participants were trained in intensive therapy, care was transferred to community providers, and the difference in HbA1c between treatment groups narrowed and disappeared. Our objective was to describe the outcomes and the quality-of-life and costs associated with those outcomes in participants who maintained excellent vs. poor glycemic control over 30 years. RESEARCH DESIGN AND METHODS: We assessed the incidence of retinopathy, nephropathy, neuropathy, cardiovascular disease, acute metabolic complications, death, quality-of-life, and costs in the tertile of DCCT intensive therapy participants who achieved a mean updated HbA1c of <7.2% (55 mmol/mol) and the tertile of DCCT conventional therapy participants (n = 240) who achieved a mean updated HbA1c of >8.8% (73 mmol/mol) over 30 years. RESULTS: Thirty years of excellent vs. poor glycemic control substantially reduced the incidence of retinopathy requiring laser therapy (5% vs. 45%), end-stage renal disease (0% vs. 5%), clinical neuropathy (15% vs. 50%), myocardial infarction (3% vs. 5%), stroke (0.4% vs. 2%), and death (6% vs. 20%). It also resulted in a gain of ~1.62 quality-adjusted life-years and averted ~$90,900 in costs of complications per participant. CONCLUSIONS: Thirty years of excellent vs. poor glycemic control for T1DM can substantially reduce the incidence of complications, comorbidities, and death, improve quality-of-life, and reduce costs. These estimates represent the benefits that may be achieved with excellent glycemic control.
Authors: Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: William H Herman; Barbara H Braffett; Shihchen Kuo; Joyce M Lee; Michael Brandle; Alan M Jacobson; Lisa A Prosser; John M Lachin Journal: J Diabetes Complications Date: 2018-06-12 Impact factor: 2.852
Authors: Florentino Carral San Laureano; Mariana Tomé Fernández-Ladreda; Ana Isabel Jiménez Millán; Concepción García Calzado; María Del Carmen Ayala Ortega Journal: J Investig Med Date: 2021-03-26 Impact factor: 2.895
Authors: Sanjeev N Mehta; Liane J Tinsley; Davida Kruger; Bruce Bode; Jennifer E Layne; Lauren M Huyett; Kate Dryga; Bonnie Dumais; Trang T Ly; Lori M Laffel Journal: Clin Diabetes Date: 2021-01
Authors: Eric Renard; Hiroshi Ikegami; André Gustavo Daher Vianna; Paolo Pozzilli; Sandrine Brette; Zsolt Bosnyak; Felipe Lauand; Anne Peters; Valerie Pilorget; Dubravka Jurišić-Eržen; Jothydev Kesavadev; Jochen Seufert; Emma G Wilmot Journal: Diabetes Metab Res Rev Date: 2021-03-02 Impact factor: 4.876